This page addresses follow-up questions and additional information pertinent to our webinar
ICD-10-CM Code Updates FY 2027: What’s New, What’s Changed, and Why It Matters.

** The coding information and guidance are valid at the time of publishing. Learners are encouraged to research
subsequent official guidance in the areas associated with the topic as they can change rapidly.

Q:  Hypoglycemia is common in patients who have undergone bariatric surgery. Should code E89.830, Postbariatric hypoglycemia, be assigned whenever a patient with a history of bariatric surgery experiences hypoglycemia?​

A:  No. Code E89.830, Postbariatric hypoglycemia, should be assigned only when the provider diagnoses and documents postbariatric hypoglycemia (PBH). Although hypoglycemia may occur in approximately 75% of patients following bariatric surgery, only a minority experience the recurrent hypoglycemic episodes associated with PBH. Therefore, a history of bariatric surgery combined with hypoglycemia is not sufficient to assume a diagnosis of PBH.​

Coding takeaway: Do not assign E89.830 based solely on a history of bariatric surgery and the presence of hypoglycemia. The medical record should support a diagnosis of postbariatric hypoglycemia.​

Q: How does the Arcevo™ LSA Hybrid Stent Graft differ from the NEXUS® Aortic Arch Stent Graft System?

A: The key difference is the type of repair and branch vessel treated:

• Arcevo™ is a hybrid surgical/endovascular device used during open aortic arch repair. It includes a stented branch for the left subclavian artery (LSA), reducing the need for a separate surgical LSA anastomosis.
• NEXUS® is a fully endovascular, modular aortic arch system. It uses separate stent-graft components in the ascending aorta, aortic arch, and brachiocephalic artery, with an optional descending extension.

Key takeaway: Arcevo supports an open hybrid arch repair, while NEXUS provides a fully endovascular arch repair.

Q:  With the new FY 2027 codes for familial cancer syndromes associated with pathogenic BRCA1 and BRCA2 mutations, does the provider need to specifically document a “syndrome”? In oncology, we frequently see documentation such as “BRCA1 positive” or “pathogenic BRCA2 mutation” without the condition being called a syndrome.​

A:  This is an important distinction. Although pathogenic BRCA1 and BRCA2 mutations are associated with inherited cancer predisposition, coders should be cautious about using that clinical knowledge to independently translate a documented genetic finding into a syndrome diagnosis. The new codes QA1.790, Familial cancer syndrome with pathogenic BRCA1 mutation, and QA1.791, Familial cancer syndrome with pathogenic BRCA2 mutation, specifically describe a familial cancer syndrome. If the documentation only identifies a pathogenic BRCA mutation and the patient’s genetic susceptibility to cancer, the appropriate code from Z15.0-, Genetic susceptibility to malignant neoplasm, may apply. If the provider documents the familial cancer syndrome – such as hereditary breast and ovarian cancer syndrome (HBOC – the appropriate new QA1.79- code may be assigned. Coders should also pay close attention to the “Code also” instruction for Z15.0- associated with the new codes and report the patient’s documented genetic susceptibility to specific malignancies as applicable.​

The key takeaway: Understand the clinical significance of a BRCA mutation, but don’t use that knowledge to diagnose a familial cancer syndrome that isn’t supported by the provider’s documentation. Follow the documentation and applicable ICD-10-CM instructional notes, and query the provider when clarification is needed.​

Q:  What is the difference between a personal history of surgical gender transition and a personal history of intersex surgery?​

A:  The key distinction is why the surgery was performed and the underlying clinical context.​

• A personal history of surgical gender transition refers to surgery performed as part of a gender transition. These procedures are intended to alter physical sex characteristics to align the body with the individual’s gender identity and may include chest or breast surgery, genital surgery, gonadectomy, or other gender-affirming procedures.​
• A personal history of intersex surgery refers to surgery associated with a congenital difference/disorder of sex development (DSD). These conditions involve variations in chromosomes, gonads, reproductive anatomy, or genital development. Surgery may have been performed during infancy, childhood, or adulthood to address anatomy, function, health risks, or sex assignment.​

Coding takeaway: The distinction is not necessarily the specific procedure performed. Similar procedures may occur in different clinical circumstances. The reason for the surgery and the provider’s documentation of the clinical context are essential for distinguishing a history of surgical gender transition from a history of intersex surgery.​